海翔药业(002099)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002099 海翔药业

已收盘 06-05 15:00:00

{"stockData":{"symbol":"002099","market":"SZ","secType":"STK","nameCN":"海翔药业","latestPrice":5.58,"timestamp":1780643013000,"preClose":5.72,"halted":0,"volume":28575234,"delay":0,"changeRate":-0.0245,"floatShares":1616000000,"shares":1619000000,"eps":-0.0457,"marketStatus":"已收盘","change":-0.14,"latestTime":"06-05 15:00:00","open":5.79,"high":5.84,"low":5.55,"amount":162000000,"amplitude":0.0507,"askPrice":5.59,"askSize":39,"bidPrice":5.58,"bidSize":369,"shortable":0,"etf":0,"ttmEps":-0.0457,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780882200000},"marketStatusCode":5,"adr":0,"adjPreClose":5.72,"symbolType":"stock","openAndCloseTimeList":[[1780623000000,1780630200000],[1780635600000,1780642800000]],"highLimit":6.29,"lowLimit":5.15,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1618715253,"isCdr":false,"pbRate":1.87,"roa":"--","roe":"0.53%","epsLYR":-0.06,"committee":0.655144,"marketValue":9032000000,"turnoverRate":0.0177,"status":1,"floatMarketCap":9016000000},"requestUrl":"/m/hq/s/002099/","defaultTab":"news","newsList":[{"id":"2641975195","title":"海翔药业：截至5月29日公司股东人数为34563人","url":"https://stock-news.laohu8.com/highlight/detail?id=2641975195","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641975195?lang=zh_cn&edition=full","pubTime":"2026-06-05 08:48","pubTimestamp":1780620499,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)06月04日在投资者关系平台上答复投资者关心的问题。投资者提问：咨询一下目前美罗培南、克林霉素等原料药销售情况及公司到5月31日的股东人数海翔药业回复：您好，公司经营情况敬请关注后续披露的定期报告。截至5月29日公司股东人数为34563人。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500005649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0192","002099","BK0188","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640150303","title":"海翔药业：公司连续两年推出回购股份计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2640150303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640150303?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:48","pubTimestamp":1780577303,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，贵司内部可以看到贵司二级市场的股价吧，对于贵司股价连续暴跌有何感想？连续暴跌有没有内查原因？是否有具体的市值管理方案？谢谢。海翔药业回复：您好，二级市场股价波动受多种因素影响，与宏观环境、政策因素、行业经营状况及资本市场风格等综合情况密切相关，敬请注意投资风险。公司始终立足主业，聚焦市场需求，致力于提升经营质量，不断夯实基本面价值。公司连续两年推出回购股份计划，维护公司全体股东利益。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400039291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0077","BK0188","BK0239","BK0192","002099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638944946","title":"海翔药业（002099）披露为子公司提供担保的进展公告，5月28日股价上涨1.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638944946","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638944946?lang=zh_cn&edition=full","pubTime":"2026-05-28 22:55","pubTimestamp":1779980112,"startTime":"0","endTime":"0","summary":"截至2026年5月28日收盘，海翔药业报收于5.41元，较前一交易日上涨1.12%，最新总市值为87.57亿元。近日，浙江海翔药业股份有限公司与汇丰银行（中国）有限公司重新签署《保证书》，继续为合并报表范围内子公司港翔国际控股（香港）有限公司提供880万美元的连带责任担保，担保额度较此前减少770万美元，担保期限为1年。本次担保为原担保展期。截至2026年5月27日，公司对子公司担保总额为28,468.02万元，担保余额为6,129.63万元，无逾期对外担保。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800043629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0188","BK0077","BK0239","BK0028","002099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638351535","title":"海翔药业：截至5月20日公司股东人数为35190人","url":"https://stock-news.laohu8.com/highlight/detail?id=2638351535","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638351535?lang=zh_cn&edition=full","pubTime":"2026-05-25 15:45","pubTimestamp":1779695110,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)05月25日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，请问公司到五月二十日的股东人数，谢谢海翔药业回复：您好，截至5月20日公司股东人数为35190人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500016997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0188","BK0077","BK0239","BK0028","002099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638953300","title":"海翔药业：目前双方合作正常开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2638953300","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638953300?lang=zh_cn&edition=full","pubTime":"2026-05-25 15:39","pubTimestamp":1779694746,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)05月25日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请详细说明和万邦德的合作进展和现状？谢谢。海翔药业回复：您好，根据双方签订的《创新药合作协议》：万邦德以自有团队和资源，具体实施WP205产品研发、上市、授权、销售等各项工作。公司按照约定提供资金并取得相关收益权。目前双方合作正常开展。感谢您对公司的关注！以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500016102.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0192","BK0239","BK0077","002099","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637391887","title":"海翔药业(002099.SZ)参投公司创新药注射用重组巴曲酶获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2637391887","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637391887?lang=zh_cn&edition=full","pubTime":"2026-05-22 15:45","pubTimestamp":1779435906,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海翔药业 发布公告，公司近日收到旗下产业基金管理人北京国信中数投资管理有限公司出具的《通知函》。公司获悉北京国信海翔股权投资合伙企业参投公司北京格瑞特森生物医药科技有限公司自主研发的创新生物药注射用重组巴曲酶收到国家药品监督管理局正式核发的《药物临床试验批准通知书》，同意本品开展临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002099","BK0192","06978","BK0188","BK0239","BK1161","BK1574","159992","BK0077","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636479418","title":"海翔药业：公司连续两年推出回购股份计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2636479418","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636479418?lang=zh_cn&edition=full","pubTime":"2026-05-20 20:52","pubTimestamp":1779281564,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业05月19日在投资者关系平台上答复投资者关心的问题。公司连续两年推出回购股份计划，维护公司全体股东利益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000041304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002099","BK0192","BK0028","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636585710","title":"海翔药业（002099）披露2025年度股东会决议公告，5月19日股价下跌1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636585710","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636585710?lang=zh_cn&edition=full","pubTime":"2026-05-19 22:44","pubTimestamp":1779201855,"startTime":"0","endTime":"0","summary":"截至2026年5月19日收盘，海翔药业报收于5.79元，较前一交易日下跌1.7%，最新总市值为93.72亿元。该股当日开盘5.84元，最高5.93元，最低5.68元，成交额达1.28亿元，换手率为1.36%。近日，浙江海翔药业股份有限公司披露《2025年度股东会决议公告》。公告显示，公司于2026年5月19日召开2025年度股东会，审议通过了《2025年度董事会工作报告》《2025年度财务决算报告》《2025年年度报告及摘要》《2025年度利润分配预案》等12项议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900044218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0028","BK0188","BK0077","002099","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635706998","title":"海翔药业：不存在关联方资金占用、违规担保情形","url":"https://stock-news.laohu8.com/highlight/detail?id=2635706998","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635706998?lang=zh_cn&edition=full","pubTime":"2026-05-15 15:18","pubTimestamp":1778829502,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)05月15日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司账面3.7亿元存疑资金的核查目前进展如何？是否存在关联方资金占用、违规担保情形？后续计划何时完成全面核查并向市场公开详细说明？海翔药业回复：您好！公司审计机构天健会计师事务所（特殊普通合伙）已对公司2025年度财务报告和内部控制情况出具了标准无保留意见的审计报告，不存在您所述情形，请勿揣测。感谢您对公司关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500021789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0028","002099","BK0192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635706620","title":"海翔药业：公司目前生产经营活动正常有序","url":"https://stock-news.laohu8.com/highlight/detail?id=2635706620","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635706620?lang=zh_cn&edition=full","pubTime":"2026-05-15 15:15","pubTimestamp":1778829322,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业05月15日在投资者关系平台上答复投资者关心的问题。咨询一下目前公司的主要产品美罗培南、克林霉素等原料药价格有没有企稳回升。活性染料连续涨价，公司目前的产能利用率是多少，是否比以前提升。公司目前生产经营活动正常有序，在手订单储备与产能利用率相匹配。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500021758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0028","002099","BK0239","BK0192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635706317","title":"海翔药业：公司严格按照相关法律法规进行信息披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2635706317","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635706317?lang=zh_cn&edition=full","pubTime":"2026-05-15 15:12","pubTimestamp":1778829139,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)05月15日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价连续大跌，是否有未披露的负面消息？公司股价连续大跌的情况下，有没有具体的市值管理方案和举措？如果保障投资者利益？海翔药业回复：您好，公司严格按照相关法律法规进行信息披露，不存在应披露而未披露事项。二级市场股价波动受多种因素影响，与宏观环境、政策因素、行业经营状况及资本市场风格等综合情况密切相关，敬请注意投资风险。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500021748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0188","002099","BK0077","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635706312","title":"海翔药业：金沣医化主要为公司医药板块部分产品配套生产中间体、起始物料等","url":"https://stock-news.laohu8.com/highlight/detail?id=2635706312","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635706312?lang=zh_cn&edition=full","pubTime":"2026-05-15 15:12","pubTimestamp":1778829139,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)05月15日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，台州金沣医药化工有限公司对公司燃料产能大约占比多少，目前是否还在生产？海翔药业回复：您好，金沣医化主要为公司医药板块部分产品配套生产中间体、起始物料等，不涉及染料产品的生产与销售。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500021747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK0239","BK1515","BK1574","BK1161","BK0028","BK0077","159938","002099","BK0192","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635376277","title":"股市必读：海翔药业（002099）5月13日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2635376277","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635376277?lang=zh_cn&edition=full","pubTime":"2026-05-14 02:48","pubTimestamp":1778698093,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，海翔药业报收于5.98元，下跌1.97%，换手率1.63%，成交量26.29万手，成交额1.58亿元。董秘最新回复投资者： 公司的活性蓝可应用于新能源电池吗？投资者： 请问到5月10日公司股东人数董秘： 您好，截至5月8日公司股东人数为35451人。投资者： 尊敬的董秘请问，贵司投资了 300055万邦达，现在300055万邦达即将st，那这事对贵司业绩有何影响董秘： 您好，公司未投资万邦达。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400002108.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0192","BK0188","BK0028","002099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635207411","title":"海翔药业：截至5月8日公司股东人数为35451人","url":"https://stock-news.laohu8.com/highlight/detail?id=2635207411","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635207411?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:34","pubTimestamp":1778664871,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)05月13日在投资者关系平台上答复投资者关心的问题。投资者提问：请问到5月10日公司股东人数海翔药业回复：您好，截至5月8日公司股东人数为35451人。感谢您对公司的关注！为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260513/32220936.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0192","BK0028","BK0239","002099","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635204054","title":"海翔药业：公司活性艳蓝KN-R是一种蒽醌系列活性染料","url":"https://stock-news.laohu8.com/highlight/detail?id=2635204054","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635204054?lang=zh_cn&edition=full","pubTime":"2026-05-13 16:57","pubTimestamp":1778662626,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)05月13日在投资者关系平台上答复投资者关心的问题。投资者提问：公司的活性蓝可应用于新能源电池吗？海翔药业回复：您好，公司活性艳蓝KN-R是一种蒽醌系列活性染料，拥有鲜艳色光、优良匀染性、高亲和力、高日晒牢度等优点，主要用于对棉、麻、毛、丝的染色。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300030261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002099","BK0239","BK0192","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635120405","title":"海翔药业：公司未投资万邦达（股票代码","url":"https://stock-news.laohu8.com/highlight/detail?id=2635120405","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635120405?lang=zh_cn&edition=full","pubTime":"2026-05-13 16:54","pubTimestamp":1778662445,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)05月13日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘请问，贵司投资了 300055万邦达，现在300055万邦达即将st，那这事对贵司业绩有何影响海翔药业回复：您好，公司未投资万邦达（股票代码：300055）。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300030188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0086","BK0239","BK0077","BK0101","BK0150","BK0028","BK0192","BK0135","BK0277","002099","300055"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635241669","title":"股市必读：海翔药业（002099）5月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2635241669","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635241669?lang=zh_cn&edition=full","pubTime":"2026-05-13 01:43","pubTimestamp":1778607789,"startTime":"0","endTime":"0","summary":"截至2026年5月12日收盘，海翔药业报收于6.1元，下跌0.97%，换手率2.68%，成交量43.27万手，成交额2.63亿元。公司今年1月以1.5亿元与万邦德制药签订创新药合作协议。投资者： 公司2020年员工持股计划在2025年11月公告延期时仍为十大股东，2026年一季报已退出前十，报告期减持规模较大。董秘： 您好，公司2020年员工持股计划严格遵守证监会、深交所相关法律法规履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300001818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0028","BK0188","002099","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634295709","title":"海翔药业：目前双方合作正常开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2634295709","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634295709?lang=zh_cn&edition=full","pubTime":"2026-05-12 16:01","pubTimestamp":1778572874,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)05月12日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，贵公司合作的万邦德目前由于“预付款”等财报原因ST了，公司给他的预付款1.2亿是否已经完成支付，后期如果有变数是否考虑或者在法律框架下有可能提前中止拿回投资款？还是说必须等到临床试验失败再拿回？海翔药业回复：您好，目前双方合作正常开展。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200024761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0028","002099","BK0239","BK0192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634295031","title":"海翔药业：建立长效激励机制，吸引和留住核心人才","url":"https://stock-news.laohu8.com/highlight/detail?id=2634295031","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634295031?lang=zh_cn&edition=full","pubTime":"2026-05-12 16:01","pubTimestamp":1778572869,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业05月12日在投资者关系平台上答复投资者关心的问题。回购的股份用于员工激励，回购成本是所有股东承担后面需要利润来计提，但是利益是个别人的。公司员工持股计划的实施严格遵循证监会、深交所相关法律法规。公司始终高度重视股东权益保护，推出实施员工持股计划的核心目的是建立长效激励机制，吸引和留住核心人才，将员工个人利益与公司长期发展深度绑定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200024750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0188","BK0239","BK0028","002099","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633164957","title":"海翔药业：截至4月30日公司股东人数为35713人","url":"https://stock-news.laohu8.com/highlight/detail?id=2633164957","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633164957?lang=zh_cn&edition=full","pubTime":"2026-05-07 09:03","pubTimestamp":1778115803,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)05月06日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2026年4月 30日公司的股东总数是多少？谢谢海翔药业回复：您好，截至4月30日公司股东人数为35713人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700005771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0028","BK0188","002099","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780859153955,"stockEarnings":[{"period":"1week","weight":0.0109},{"period":"1month","weight":-0.1072},{"period":"3month","weight":-0.256},{"period":"6month","weight":-0.0912},{"period":"1year","weight":-0.0558},{"period":"ytd","weight":-0.1058}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0318},{"period":"3month","weight":-0.0234},{"period":"6month","weight":0.032},{"period":"1year","weight":0.1902},{"period":"ytd","weight":0.0148}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江海翔药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"34563人(较上一季度减少1.78%)","perCapita":"46747股","listingDate":"2006-12-26","address":"浙江省台州市椒江区外沙支路100号","registeredCapital":"161871万元","survey":"　　浙江海翔药业股份有限公司的主营业务是原料药及医药中间体、染料及染颜料中间体的研发、生产和销售。公司的主要产品是蒽醌系列染料产品、中间体。公司企业技术中心被认定为“国家级企业技术中心”，拥有国家级博士后工作站，已承担完成国家级项目14项，省级项目35项，拥有国内发明专利67项、PCT专利4项，荣获浙江省级科技奖项11项。","listedPrice":11.56},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海翔药业(002099)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海翔药业(002099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海翔药业,002099,海翔药业股票,海翔药业股票老虎,海翔药业股票老虎国际,海翔药业行情,海翔药业股票行情,海翔药业股价,海翔药业股市,海翔药业股票价格,海翔药业股票交易,海翔药业股票购买,海翔药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海翔药业(002099)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海翔药业(002099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}